Platform & Pipeline
Lead Product.
DUO-207: replacing gemcitabine + paclitaxel as a next-generation chemotherapy backbone.
What is DUO-207?
Single-infusion, tumor-activated prodrug combining gemcitabine and paclitaxel.
Why it matters now?
KRASi momentum makes the GEM + PTX backbone strategically important.
How is DUO-207 differentiated?
Tumor pharmacology with long retention and shorter systemic exposure.
Evidence package:
PDX efficacy, survival benefit, completed GLP toxicology, orphan drug designations, favorable FDA Pre-IND feedback, and regulatory ethics approval.
Clinical strategy:
Adaptive Phase 1b/2 trial across pancreatic, lung, and breast cancer to generate partnering-grade data.
DUO-207 (light blue) halts the growth of human derived tumors that remain unchecked by standard of care (dark blue). Negative control shown in red.